Abstract
Widespread reliance on animal models during preclinical research and toxicity testing assumes their reasonable predictivity for human outcomes. However, of 20 published systematic reviews examining human clinical utility, located during a comprehensive literature search, animal models demonstrated significant potential to contribute toward the development of clinical interventions in only two cases, one of which was contentious. Included were experiments expected by ethics committees to lead to medical advances, highlycited experiments published in major journals, and chimpanzee experiments — the species most generally predictive of human outcomes. Seven additional reviews failed to demonstrate utility in reliably predicting human toxicological outcomes such as carcinogenicity and teratogenicity. Results in animal models were frequently equivocal, or inconsistent with human outcomes. Consequently, animal data may not generally be considered useful for these purposes. Regulatory acceptance of non-animal models is normally conditional on formal scientific validation. In contrast, animal models are simply assumed to be predictive of human outcomes. These results demonstrate the invalidity of such assumptions. The poor human clinical and toxicological utility of animal models, combined with their generally substantial animal welfare and economic costs, necessitate considerably greater rigor within animal studies, and justify a ban on the use of animal models lacking scientific data clearly establishing their human predictivity or utility.
Keywords: Animal experiment, animal model, animal study, clinical trial, human healthcare, systematic review
Reviews on Recent Clinical Trials
Title: Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare
Volume: 3 Issue: 2
Author(s): Andrew Knight
Affiliation:
Keywords: Animal experiment, animal model, animal study, clinical trial, human healthcare, systematic review
Abstract: Widespread reliance on animal models during preclinical research and toxicity testing assumes their reasonable predictivity for human outcomes. However, of 20 published systematic reviews examining human clinical utility, located during a comprehensive literature search, animal models demonstrated significant potential to contribute toward the development of clinical interventions in only two cases, one of which was contentious. Included were experiments expected by ethics committees to lead to medical advances, highlycited experiments published in major journals, and chimpanzee experiments — the species most generally predictive of human outcomes. Seven additional reviews failed to demonstrate utility in reliably predicting human toxicological outcomes such as carcinogenicity and teratogenicity. Results in animal models were frequently equivocal, or inconsistent with human outcomes. Consequently, animal data may not generally be considered useful for these purposes. Regulatory acceptance of non-animal models is normally conditional on formal scientific validation. In contrast, animal models are simply assumed to be predictive of human outcomes. These results demonstrate the invalidity of such assumptions. The poor human clinical and toxicological utility of animal models, combined with their generally substantial animal welfare and economic costs, necessitate considerably greater rigor within animal studies, and justify a ban on the use of animal models lacking scientific data clearly establishing their human predictivity or utility.
Export Options
About this article
Cite this article as:
Knight Andrew, Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare, Reviews on Recent Clinical Trials 2008; 3(2) . https://dx.doi.org/10.2174/157488708784223844
DOI https://dx.doi.org/10.2174/157488708784223844 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development
Current Pharmaceutical Design Non-Microbicidal Control of Bacterial Biofilms with Small Molecules
Anti-Infective Agents Mechanisms of Drug Hypersensitivity Reactions and the Skin
Recent Patents on Inflammation & Allergy Drug Discovery Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Recent Developments in Antithrombotic Therapy: Will Sodium Warfarin Be a Drug of the Past?
Recent Patents on Cardiovascular Drug Discovery Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Bacteremic Streptococcus pneumoniae in Community-Acquired Pneumonia: An Update
Current Respiratory Medicine Reviews Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Receptor Binding Ligands to Image Infection
Current Pharmaceutical Design New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Virtual Screening for the Development of New Effective Compounds Against Staphylococcus aureus
Current Medicinal Chemistry Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem
Infectious Disorders - Drug Targets Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Current Research on Opioid Receptor Function
Current Drug Targets